RESUMO
AimThe present study discussed the humoral immune response and antibody dynamics after primary and booster immunity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines among patients with chronic liver disease (CLD) in the real world. Thus, it provided data to develop SARS-CoV-2 vaccination strategy. MethodsPatients with confirmed CLD and completed primary or booster immunity of SARS-CoV-2 vaccines were enrolled. Serological specimens were collected after primary or booster immunity of SARS-CoV-2 vaccines to detect novel coronavirus neutralizing antibody (nCoV NTAb) and novel coronavirus spike receptor-binding domain antibody (nCoV S-RBD). Thus, we could evaluate the humoral immune response and antibody dynamics after primary and booster immunity of SARS-CoV-2 vaccines among patients with CLD. Simultaneously, baseline demographics, liver disease-related situations, comorbidity-related situations, SARS-CoV-2 vaccination information, and laboratory examination-related indicators of patients were collected. ResultsA total of 315 patients received SARS-CoV-2 vaccines, including 223 patients who completed the primary immunity of SARS-CoV-2 vaccines, 114 patients who completed booster immunity of SARS-CoV-2 vaccines, and 22 patients who underwent the antibody detection of SARS-CoV-2 vaccines after both primary and booster immunities. The positive rate of nCoV NTAb was 59.64% in Primary and 87.72% in Booster (P<0.001). The median level of nCoV NTAb was 11.53 AU/mL in Primary and 31.98 AU/mL in Booster (P<0.001). The positive rate of nCoV S-RBD was 69.06% in Primary and 91.23% in Booster (P<0.001). The median level of nCoV S-RBD was 21.60AU/mL in Primary and 112.65 AU/mL in Booster (P<0.001). After booster immunity of SARS-CoV-2 vaccines in 22 patients, the positive rate of nCoV NTAb increased from 59.09% to 86.36%, and that of nCoV S-RBD increased from 68.18% to 90.91%. The median level of nCoV NTAb increased from 11.24 AU /mL to 59.14 AU /mL after booster immunity. The median level of nCoV S-RBD increased from 27.28 AU/mL to 219.10 AU/mL. Compared to the antibody level of primary immunity, the median level of nCoV NTAb and nCoV S-RBD in 22 patients was increased by 5.26 and 8.03 times, respectively. Among 22 patients, 9 were negative for nCoV NTAb after primary immunity, while 6 were transformed positive after booster immunity, and the positive conversion rate of nCoV NTAb was 66.7%. On the other hand, 7 patients were negative for nCoV S-RBD after primary immunity, while 5 were transformed positive after booster immunity, and the positive conversion rate of nCoV S-RBD was 71.4%. ConclusionPatients with CLD show improved humoral immune response after completing primary and booster immunity of SARS-CoV-2 vaccines, while booster immunity further improves the positive rate and antibody level of patients with CLD. Finally, the positive conversion rate among patients with primary immunity failure also can be improved after booster immunity.
RESUMO
ObjectiveTo systematically review the clinical effect of transcatheter arterial chemoembolization with drug-eluting beads (DEB-TACE) versus conventional transcatheter arterial chemoembolization (cTACE) in the treatment of unresectable liver cancer. MethodsPubMed, Embase, Cochrane, and CNKI were searched for articles on clinical control trials of DEB-TACE versus cTACE in the treatment of unresectable liver cancer. The articles were screened according to inclusion and exclusion criteria, and after valid data were extracted, Revman 5.3 software was used for meta-analysis. The two groups were compared in terms of the number of patients with complete remission (CR), partial remission (PR), or stable disease (SD) and 6- and 12-month survival rates. ResultsA total of 12 articles were included, with 1177 patients in total, among whom 519 patients underwent DEB-TACE and 658 underwent cTACE. Compared with the cTACE group, the DEB-TACE group had a significantly higher number of patients with CR (risk ratio ［RR］=1.42, 95% confidence interval ［CI］: 1.18-1.72, P=0.0002), and had a significantly higher 12-month survival rate (RR=1.09, 95% CI: 1.01-1.17, P=0.03). There were no significant differences between the two groups in the number of patients with PR (RR=1.13, 95% CI: 0.97-130, P=0.12), the number of patients with SD (RR=0.82, 95% CI: 0.64-1.05, P=0.12), 6-month survival rate (RR=1.05, 95% CI: 1.00-1.10, P=0.07). ConclusionDEB-TACE has a better therapeutic effect than cTACE with iodinated oil.
